

# Human Papillomavirus Vaccines Session

Peter Szilagyi, MD, MPH  
ACIP HPV Vaccines Work Group Chair

Advisory Committee on Immunization Practices  
February 27, 2019

# HPV vaccination policy issue being addressed by the Work Group

- Should HPV vaccination be recommended for persons aged 27 through 45 years who were not previously vaccinated?

## Expanded age indication for 9-valent HPV vaccine

- Manufacturer filed a sBLA in April 2018 to expand the age indication for 9-valent HPV vaccine (9vHPV) from age 9–26 years to age 9–45 years
- Approved by FDA in October 2018
- 9-valent HPV vaccine is the only HPV vaccine currently available in the United States

# Past ACIP HPV vaccine sessions, mid-adult vaccination

## June 2018

- Overview and history of application for licensure in mid-adults
- HPV epidemiology, natural history and burden of disease
- Clinical trial data included in sBLA

## October 2018

- Regulatory basis for licensure
- U.S. vaccination program
  - Coverage and impact on infection/disease
- HPV epidemiology and sexual behavior
- Post-licensure effectiveness studies
- Global HPV vaccination & vaccine supply
- GRADE
  - Efficacy, immunogenicity, safety
- Preliminary health economic analyses
- Policy considerations

Mid-adults, ages 27–45 years

sBLA, Supplemental Biologics License Application

# ACIP HPV Vaccines Work Group – topics reviewed related to mid-adult vaccination since October 2018

- Impact modeling and health economic analyses
- HPV epidemiology and natural history
- Values and acceptability to stakeholders
- Recommendation options for consideration

# Modeling and health economic analyses for mid-adult HPV vaccination

- Three models were initially providing evidence for this policy question
- All still going through CDC/ACIP economic review at the time of the October 2018 ACIP meeting
  - Differences in results across models – preliminary data presented
- Several Work Group calls have been devoted to this topic

# Today's HPV Vaccines Session

- Overview and Background  
Dr. Lauri Markowitz, CDC/NCIRD
- Impact and Cost Effectiveness, Mid-adult HPV Vaccination  
Dr. Marc Brisson, Laval University
- Overview of Health Economic Results from 4 Modeling Groups  
Dr. Harrell Chesson, CDC/NCHHSTP
- Mid-adult HPV Vaccination: Patient Values and Acceptability  
Dr. Nancy McClung, CDC/NCIRD
- Program and Vaccine Provider Surveys  
Dr. Elissa Meites, CDC/NCIRD
- Work Group Considerations  
Dr. Lauri Markowitz, CDC/NCIRD

# ACIP HPV Vaccines Work Group

## ■ ACIP Members

- Peter Szilagyi (Chair)
- Jose Romero
- Kevin Ault

## ■ Ex Officio Members

- Jeff Roberts (FDA)
- Joohee Lee (FDA)

## ■ CDC Lead

- Lauri Markowitz

## ■ Liaison Representatives

- Shelley Deeks (NACCI)
- Linda Eckert (ACOG)
- Sandra Fryhofer (ACP)
- Amy Middleman (SAHM)
- Chris Nyquist (AAP)
- Sean O'Leary (PIDS)
- Robin O'Meara (AAFP)
- Patricia Whitley-Williams (NMA)
- Jane Zucker (AIM)

## ■ Consultants

- Joseph Bocchini
- Tamera Coyne-Beasley
- John Douglas
- Allison Kempe
- Aimee Kreimer (NCI)
- Debbie Saslow (ACS)
- Rodney Willoughby
- Rachel Winer

## CDC Contributors

- Harrell Chesson
- Julianne Gee
- Elissa Meites
- Jeanne Santoli
- Mona Saraiya
- John Su
- Shannon Stokley
- Lakshmi Panagiotakogoulos
- Elizabeth Unger
- Charnetta Williams